PRESS RELEASES

Coulter Partners Successfully Places Three Senior Executives at Augustine Therapeutics

Augustine Therapeutics is a biotechnology company focused on developing new therapies for neuromuscular, neurodegenerative and cardio-metabolic diseases through the inhibition of the Histone DeACetylase 6 (HDAC6) enzyme.

Commenting on the appointments, Gerhard Koenig, PhD, CEO of Augustine, said: “Augustine is pioneering a new generation of HDAC6 inhibitors and has recently achieved a significant milestone by initiating its first clinical trial of lead candidate AGT-100216 for the treatment of Charcot-Marie-Tooth disease. To support the Company’s growth, we have significantly strengthened the management team and are delighted to welcome these new additions to our executive team. We extend our sincere thanks to Coulter Partners for their outstanding work in identifying and sourcing such high-caliber talent, whose expertise perfectly aligns with our strategic growth and clinical ambitions.”